Released Aug 6, 2025, after the close
10-Q filed Aug 6, 2025, 37 days after period end · 0001628280-25-038422
Q2 2025 · 10-Q
Revenue$45.60M$45.60M −2.2% vs Q2 2024+10.0% vs Q1 2025
Net Income-$5.58M-$5.58M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.04-$0.04 N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$23,867,000−6.2%
Operating Income-$10,624,000N/M
Operating Cash Flowderived$108,000−98.3%
Free Cash Flowderived-$1,469,000N/M
Margins · derived
Gross margin52.3%−2.2 pt vs Q2 2024
Operating margin-23.3%−5.0 pt vs Q2 2024
Net margin-12.2%+10.1 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $45.60M | $46.62M | $49.69M | $40.16M |
| Net Income | -$5.58M | -$10.43M | -$4.39M | -$702.00K |
| EPS Diluted | -$0.04 | -$0.08 | -$0.03 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR